{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-23-000005","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.116462+00:00","generated_at":"2026-06-15T22:23:37.270009+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera Q1 2023 revenue $12M, net loss $0.14 EPS vs $0.59 EPS profit in Q1 2022","bullets":["Total revenue $12.2M, down from $316.6M in Q1 2022; net loss $40.1M vs net income $168.6M.","EPS loss $0.14 basic/diluted versus EPS profit $0.59 basic/0.54 diluted a year ago.","Partnered program starts reached 101 cumulative (up 20% YoY); 9 molecules in clinic (up from 6).","R&D spending rose to $52.6M from $26.4M; cash and marketable securities $821.5M.","Management highlighted T-cell engager platform progress; no guidance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-23-000005","json":"https://secwatch.observer/filing/0001703057-23-000005.json","markdown":"https://secwatch.observer/filing/0001703057-23-000005.md","text":"https://secwatch.observer/filing/0001703057-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000005/0001703057-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000005/abcl-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:23:37.270009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}